Insider Purchases: Inside the Buy
Tag: Gene Editing
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
CEO Bought Shares of Vertex Pharmaceuticals (VRTX) A Bit Higher Back in August: Great Biotech At A Fair Price. Wait For Additional Pull-Back?
Vertex is more than cystic fibrosis drugs. With gene editing, pain relief, and even a potential T1D cure, the CEO’s insider buy raises one question: buy now or wait for additional pullback?
Moderna (MRNA): The Biotech Rollercoaster – Will This Gene Editor Reach the Top? 🎢💉
Moderna (MRNA) might be on the downhill since its peak in 2021, but its remarkable mRNA platform is fueling new therapeutic breakthroughs. With strong insider bets, a healthy pipeline, and institutional backing, Moderna could be an intriguing long-term play for investors. However, risks like intense competition and COVID sales deceleration remain. Should you bet on Moderna’s future or stay on the sidelines? Here’s what you need to know.